Guo Wei Email & Phone Number

Cambridge, Massachusetts, United States

• Led drug discovery teams to discover therapeutics to oncology and immuno-oncology targets, using multiple modalities, including small molecule inhibitor, degrader (e.g. PROTAC, molecular glue), biologics, radioligand.
• Led team effort for oncology and immune-oncology target selection and validation. Established compound screen, hit-to-lead, lead… Show more
• Led team effort for oncology and immune-oncology target selection and validation. Established compound screen, hit-to-lead, lead optimization and DC candidate selection pipelines.
• Managed external collaborations, including managing CRO, industrial collaboration, academic drug discovery and research. Show less

Cambridge, Massachusetts, United States

• Planned and prioritized discovery biology strategy and workflows across company portfolio to enable go/no-go decisions.
• Led cross-function project team, including CROs, to develop next-generation BCR-ABL kinase inhibitors for the treatment of CML and Ph+ALL.

Cambridge, Massachusetts, United States

• Senior Principal Scientist (10/2021-12/2021), Principal Scientist (09/2019-09/2021)
• Identified novel oncology and immuno-oncology targets through data mining and literature search, and validated targets through RNAi and CRISPR approaches.
• Led multiple drug discovery projects, including small molecule inhibitor projects, protein degradation (PROTAC and molecular glue) projects, and achieved target validation, hit identification, and hit to lead milestone.

415 Main Street, Cambridge, MA 02142

• Senior Group Leader (07/2017-09/2019), Senior Research Scientist II (07/2016-06/2017), Group Leader (07/2015-06-2016), Senior Research Scientist I (07/2014-06/2015), Research Scientist II (07/2009-06/2014)
• Initiated and led discovery and therapeutic projects, including leading multidisciplinary research teams, designing, and executing pre-IND discovery biology projects, project management, outward facing presentations.
• Initiated and led discovery and therapeutic projects, including leading multidisciplinary research teams, designing, and executing pre-IND discovery biology projects, project management, outward facing presentations.
• Led team effort to discover MCL1 inhibitors from target validation, assay development, compound screen, hit identification, hit to lead, lead optimization, DMPK, biomarker, toxicology to IND enabling studies and.
• Developed a molecular probe (ML214) for BCL2A1/apoptosis priming through phenotypic screen of the MLPCN library and chemo-proteomics/functional characterization.
• Discovered cancer therapy biomarker and resistance mechanism through genomic analysis, CRISPR/CRISPRa screening, saturation mutagenesis, resistance characterization and PK-guided functional assays. Show less

Greater Boston Area

• Discovered rapamycin to overcome glucocorticoid resistance through novel genomics approaches and mechanism of action studies. The study led to clinical trial NCT00874562.
• Developed and executed multiplexed gene expression screens which resulted in identification of small molecules that alter the expression of apoptosis-related genes.

• Authored 12 publications (including 5 first/co-first author) in peer reviewed journals.
• Revealed the regulation and contribution of Ets-2, PTEN and Akt in inflammation and autoimmune disease, including pathology, signal transduction and regulation of cytokines and chemokines.
• Discovered the mechanism of PTEN, AKT and Ets-2 in cancer development and their contribution in tumor microenvironment.

Doctor Of Philosophy (Ph.D.), Molecular Genetics

Bachelor Of Science (Bs), Biology

Activities and Societies: Class President, Department of Biology